Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma

BACKGROUND: Daratumumab (Dara), an anti‐CD38 monoclonal antibody, has an immunologic mechanism of action through targeting of CD38 expressing immune cells in patients with multiple myeloma (MM). Furthermore, it was recently shown that CD38 upregulation in tumors, is a major mechanism of acquired res...

Descripción completa

Detalles Bibliográficos
Autores principales: Stocker, Nicolas, Gaugler, Béatrice, Ricard, Laure, de Vassoigne, Frédéric, Marjanovic, Zora, Mohty, Mohamad, Malard, Florent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064026/
https://www.ncbi.nlm.nih.gov/pubmed/31991058
http://dx.doi.org/10.1002/cam4.2827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064026/
https://www.ncbi.nlm.nih.gov/pubmed/31991058
http://dx.doi.org/10.1002/cam4.2827

Ejemplares similares